Humacyte, Inc.
Humacyte, Inc. (HUMA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Durham, United States and has 184 employees. The company is worth $119.18M. Revenue was $2.04M in fiscal 2025. It reported a net loss of $40.83M. The share price is 77.4% below its 52-week high of $1.90. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $2.03M. In that quarter, 2 of them opened or added to the position. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -96.0% over 5Y.
today you would have $47.14▼ -95.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 6 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $0.96 | $5.05 | $2.84 | $2.11 | $7.25 | $10.17 | |
| P/S | — | 104.7x | — | — | — | — | — |
| P/B | 15.5x | 68.6x | — | 25.0x | 1.9x | 6.1x | — |
| EPS | -$0.26 | -$1.26 | -$1.07 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| OTLKOutlook Therapeutics, Inc. | $0.49 | — | — | 0.00% | — | $118.85M |
| OWLTOwlet, Inc. | $4.11 | — | 5.1x | 0.00% | — | $120.1M |
| RTSNRetension Pharmaceuticals, Inc. | $14.07 | — | — | 0.00% | — | $117.23M |
| CUECue Biopharma, Inc. | $16.71 |
| -$0.12 |
| -$0.66 |
| -$11.54 |
| Profit margin | — | -2003.58% | — | — | — | — | — |
| ROE | -419.72% | -1313.38% | — | -817.78% | -10.23% | -21.67% | — |
Median of the years shown; P/E years above 200x are left out.
| — |
| 37.8x |
| 0.00% |
| -1603.48% |
| $121.39M |
| AVXLAnavex Life Sciences Corp | $1.31 | — | 1.1x | 0.00% | -12.80% | $121.43M |
| ABOSAcumen Pharmaceuticals, Inc. | $1.69 | — | 2.1x | 0.00% | -120.50% | $122.22M |